A healthcare fintech firm, we apply our AI-insights to financial services to deliver hope through better outcomes for patients investors and doctors.
Joined November 2020
- Tweets 45
- Following 32
- Followers 23
- Likes 10
31 Photos and videos
BioPhy retweeted
28 Mar 2022
Steve Truong, David Latshaw, and Dr. Dan Sciubba (all WG’21) teamed up in the #WhartonEMBA program around a goal to “fight cancer with finance.” #WhartonGrad
At the end of 2019, the cofounders officially launched @BioPhy3, a health care fintech firm: whr.tn/3ilrz5E
1
3
5
At Biophy, we are driven by our promise to deliver hope. By applying our AI-driven insights to finance, we can deliver meaningful outcomes for patients, investors and doctors.
#ai #healthcare #artificialintelligence #finance #research #biotech #startup #clinicaltrials #investing
2
3
#Clinicaltrial outcomes are a key input to biotech valuations. It’s very difficult to predict likely outcomes of trials- until now. Biophy has developed an #AI-model that predicts the likely outcome of clinical trials.
1
1
BioPhy retweeted
21 Jan 2021
Tejas is a highly valued member of our team!
1
3
#AI is revolutionizing healthcare in countless ways. We believe we can continue to transform it by using artificial intelligence to predict clinical trial successes, which can inform development decisions & help connect patients to live-saving treatments.
lnkd.in/eAAXA9gmp
3
3
BioPhy’s #AI model can see and build connections between seemingly disparate information that humans cannot.
By using these insights, BioPhy can help #investors make informed decisions and connect them to high-conviction #opportunities.
1
2
1
Because of the COVID-19 pandemic there has been an increase in remote data collection in #clinicaltrials, which will create even more opportunity for #artificialintelligence in clinical trial prediction.
lnkd.in/ec8m-ZA
1
1
1
By using AI to predict clinical trial successes, BioPhy can inform development decisions, identify high and low probabilities of success, and, most importantly, connect patients to life-saving treatments.
sources:
theconversation.com
biophy.ai
1
1
Individuals in every industry impacted by #clinicaltrials struggle to make good decisions with little information due to the unpredictable outcomes of trials.
By using BioPhy's #AI-driven engine, we can provide impacted industries data-driven solutions to their challenges.
1
1
2
Biotech is a large area of asset management. The number of clinical trials is growing- but biotech investing is often still unpredictable, volatile & risky.
We apply our AI-driven insights, using finance, to deliver meaningful &aligned outcomes for patients, investors & doctors.
1
1
Our #AI engine has demonstrated the ability to predict the likelihood of #clinicaltrial success.
What does this mean for the future of healthcare & biotech investing?
Faster, cheaper, more life-changing medical breakthroughs, along w/ reduced risk of investment decisions.
2
1
BioPhy’s quantifiable & scalable approach to investment is AI-based, continually running & improving. Our AI engine has shown the ability to predict the success & failure of clinical trials in Phases 1, 2, & 3. This allows biotech investors to make informed investment decisions.
1
1
Meet BioPhy Co-Founder & Chief Medical Officer Dr. Daniel Sciubba, professor of neurological surgery, oncology, & orthopaedic surgery at the Johns Hopkins University School of Medicine. He serves as Director of spine tumor & spinal deformity research in the Dept. of Neurosurgery.
1
1
Today we’d like to introduce you to BioPhy Co-Founder, President and Chief Financial Officer, Steve Truong. Steve, along with BioPhy's other co-founders, is an alumnus of the Wharton School.
instagram.com/p/CJeO06tpURZ/…
1
1